Thoraflex Hybrid FET is designed for the open surgical repair or replacement of aortic arch artery vessels that are damaged or diseased. Credit: Terumo Aortic.

Terumo Aortic has announced the first commercial implant of the Thoraflex Hybrid frozen elephant trunk (FET) device in the US.

Thoraflex Hybrid FET combines a Gelweave polyester graft and Nitinol self-expanding stent graft.

The single-use medical device is designed for the open surgical repair or replacement of aortic arch artery vessels that are damaged or diseased as well as for repair of the descending thoracic aorta with or without involving the ascending aorta.

In 2012, the device received CE Mark approval, followed by FDA clearance in April.

Terumo Aortic had sold more than 13,000 Thoraflex Hybrid FET devices worldwide over the last ten years.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

See Also:

Terumo Aortic North America president Paul Kuznik said: “This commercial implant represents a significant milestone for the company and a tremendous opportunity for Terumo Aortic in the United States.

“This innovative hybrid device complements our open surgical graft and endovascular portfolio, making us one of the strongest medical device companies within the aortic space, helping to deliver our commitment to provide solutions for every aorta.”

The Thoraflex Hybrid study principal investigator professor Joseph Coselli, executive vice-chair of the Cardiothoracic Surgery Division at Baylor College of Medicine US, implanted the device.

Coselli said: “The procedure was very successful, the device performed well, and the patient is making a good recovery.

“Thoraflex Hybrid is the first of its kind device used in FET repair in the United States and it will allow US physicians to treat patients who may be at great risk of rupture with a device that brings the primary benefit of requiring a single-stage procedure for those with suitably limited disease, instead of two procedures which has been the conventional pathway in the United States for this group of patients.”